StrykerSYK
SYK
About: Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
Employees: 53,000
0
Funds holding %
of 7,139 funds
0
Analysts bullish %
of 11 analysts
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
177% more first-time investments, than exits
New positions opened: 230 | Existing positions closed: 83
17% more repeat investments, than reductions
Existing positions increased: 804 | Existing positions reduced: 687
3% more funds holding
Funds holding: 1,994 [Q3] → 2,052 (+58) [Q4]
2% less capital invested
Capital invested by funds: $110B [Q3] → $107B (-$2.71B) [Q4]
6% less call options, than puts
Call options by funds: $518M | Put options by funds: $550M
2.56% less ownership
Funds ownership: 80.07% [Q3] → 77.51% (-2.56%) [Q4]
5% less funds holding in top 10
Funds holding in top 10: 75 [Q3] → 71 (-4) [Q4]
Research analyst outlook
11 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$413
8%
upside
Avg. target
$437
14%
upside
High target
$450
18%
upside
11 analyst ratings
9 positive
82%
2 neutral
18%
0 negative
0%
Barclays Matt Miksic 72% 1-year accuracy 28 / 39 met price target | 16%upside $443 | Overweight Maintained | 10 Feb 2025 |
Goldman Sachs David Roman 50% 1-year accuracy 7 / 14 met price target | 12%upside $427 | Neutral Maintained | 30 Jan 2025 |
Truist Securities Richard Newitter 77% 1-year accuracy 33 / 43 met price target | 8%upside $413 | Hold Maintained | 30 Jan 2025 |
RBC Capital Shagun Singh 63% 1-year accuracy 44 / 70 met price target | 14%upside $435 | Outperform Maintained | 29 Jan 2025 |
Wells Fargo Larry Biegelsen 66% 1-year accuracy 31 / 47 met price target | 14%upside $435 | Overweight Maintained | 29 Jan 2025 |
Financial journalist opinion
Based on 26 articles about SYK published over the past 30 days
Positive
Zacks Investment Research
20 hours ago
4 Seniors & Aging Demographics Stocks to Watch Right Now
ABBV, AMGN, SYK and DXCM are well-poised to benefit from the evolving new opportunities in Seniors & Aging Demographics within healthcare.
Positive
Schwab Network
1 day ago
The Big 3: FTNT, NXT, SYK
Dan Deming joins today's Big 3 to talk about three companies he believes may have fallen under the radar for investors. He talks about Fortinet's (FTNT) impact on cybersecurity, Nextracker's (NXT) role in solar and Stryker's (SYK) use of combining technology with health care.
Neutral
GlobeNewsWire
3 days ago
Stryker completes acquisition of Inari Medical, Inc., providing entry into the high-growth peripheral vascular segment
Portage, Michigan, Feb. 19, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK), a global leader in medical technologies, announced today that it has completed the acquisition of Inari Medical, Inc. (NASDAQ: NARI), a company that provides innovative solutions for venous thromboembolism (VTE) clot removal without the use of thrombolytic drugs. The addition of Inari brings an established peripheral vascular position to Stryker in the fast-growing VTE segment.
Positive
Zacks Investment Research
5 days ago
SYK Trades Below 52-Week High: Should You Buy, Hold or Sell the Stock?
Stryker is gaining momentum with strong Q4 results, innovative medtech solutions and high-growth market expansion. But, is the stock still a buy?
Neutral
PRNewsWire
1 week ago
Kadant Set to Join S&P SmallCap 600
NEW YORK , Feb. 13, 2025 /PRNewswire/ -- Kadant Inc. (NYSE: KAI) will replace Inari Medical Inc. (NASD: NARI) in the S&P SmallCap 600 effective prior to the opening of trading on Wednesday, February 19. S&P 500 constituent Stryker Corp. (NYSE: SYK) is acquiring Inari Medical in a deal expected to be completed soon, pending final closing conditions.
Neutral
GlobeNewsWire
1 week ago
Stryker to participate in Citi's 2025 Unplugged Medtech and Life Sciences Access Day
Portage, Michigan, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) will participate in Citi's 2025 Unplugged Medtech and Life Sciences Access Day on Thursday, February 27, 2025 at Citigroup Headquarters, New York, New York.
Neutral
GlobeNewsWire
1 week ago
Stryker announces Allan Golston will retire from Board of Directors
Portage, Michigan, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) announced today that after 14 years of distinguished service, Allan Golston has notified the company that he will not stand for re-election at Stryker's 2025 Annual Meeting of Shareholders, which is expected to be held on May 8, 2025. Golston joined Stryker's Board of Directors in 2011 and served as independent Lead Director from 2016 to 2022. He also served on the Governance and Nominating Committee and as Chair of the Compensation and Human Capital and Audit Committees. “We are grateful for Allan's many contributions to the board over the years and thank him for his strategic guidance and steadfast support of our growth ambitions,” said Kevin Lobo, Chair and Chief Executive Officer, Stryker. “We thank Allan for his leadership and dedication in helping Stryker advance our mission of making healthcare better.” Golston has served as the President, United States Program for the Bill & Melinda Gates Foundation since 2006, and as Chief Financial and Administrative Officer of the Bill & Melinda Gates Foundation from 2000 to 2006. He is also a director of Harley-Davidson, Inc., a manufacturer of motorcycles and accessories. Golston has extensive experience in auditing, finance and the healthcare industry. He is a certified public accountant and has held hospital finance executive positions. In his service to the Gates Foundation, he has contributed to the strategic formation and operation of successful initiatives to provide healthcare, education and other human needs, all of which gave him an understanding that assisted Stryker in its global efforts to meet the needs of patients and caregivers. About Stryker
Positive
FXEmpire
3 weeks ago
Sales Growth, Strategic Acquisitions Drive Stryker Higher
Medical device maker Stryker Corporation (SYK) benefits from more procedures, sales, and acquisitions.
Positive
Zacks Investment Research
3 weeks ago
Will Cheaper AI Models Like DeepSeek Become a Boon? 3 Stocks to Watch
As costs related to AI models may come down, as is evident from the cheaper DeepSeek model from China, MedTech companies developing AI-based solutions like SYK, BSX and TEM are likely to gain.
Positive
Benzinga
3 weeks ago
Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth
Wall Street analysts rerated Stryker Corp SYK Wednesday after the company's fourth-quarter print.
Charts implemented using Lightweight Charts™